🇺🇸 FDA
Patent

US 8808684

Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction

granted A61KA61K31/522A61K45/06

Quick answer

US patent 8808684 (Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/522, A61K45/06, A61K48/0008, A61K48/005